Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation

Journal of Hepatology

Volumn 34, Issue 6, 2001, Pages 888-894

  Naoumov, Nikolai V ^a   Lopes, A Ross ^a   Burra, Patrizia ^b   Caccamo, Lucio ^c   Iemmolo, Rosa M ^d   De Man, Robert A ^e   Bassendine, Margaret ^f   O'Grady, John G ^g   Portmann, Bernard C ^g   Anschuetz, Gaya ^h   Barrett, Catherine A ^h   Williams, Roger ^a   Atkins, Mark ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PADOVA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Istituto di Medicina Interna di Padova   (Italy)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f FREEMAN HOSPITAL   (United Kingdom)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Hepatitis B immunoglobulin; Hepatitis B virus; Hepatitis B virus recurrence; Liver transplantation

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; INFECTION PREVENTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; RECURRENCE;

EID: 0034954042     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00039-3     Document Type: Article

References (35)

1. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
2. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications
3. Passive immunoprophylaxis after liver transplantation in HbsAg-positive patients
4. Liver transplantation in HBs antigen (HbsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization
5. Liver transplantation in European patients with the hepatitis B surface antigen
6. Long-term results of liver transplantation in HBsAg positive patients receiving anti-HBs passive immunoprophylaxis
7. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
8. Hepatitis B envelope protein mutants
9. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
10. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
11. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
12. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
13. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European concerted action on viral hepatitis
14. A one-year trial of lamivudine for chronic hepatitis B
15. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection
16. Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alpha treatment
17. Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection
18. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
19. Lamivudine after hepatitis B immunoglobulin is effective in preventing hepatitis B recurrence after liver transplantation
20. Combined short-term hepatitis B immunoglobulin (HBIg) and long-term lamivudine (Lam) versus HBIg monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients
21. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model
22. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients
23. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection
24. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
25. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
26. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin
27. Combination low dose hepatitis B immune globulin (HBIg) and lamivudine therapy provides effective prophylaxis against post transplant hepatitis B
28. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination: A new strategy in the prophylaxis of hepatitis B recurrence after liver transplantation
29. Antigenic characterisation of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin
30. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response
31. Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance
32. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients
33. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
34. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
35. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy